Noscapine Repurposing in Cancer Therapy: Mechanistic Insights, Resistance Modulation, and Translational Challenges

Microtubule-targeting agents continue to play a central role in cancer treatment; however, they are associated with dose-toxicity relationships, narrow therapeutic windows, and rapid drug resistance. Developing alternatives that inhibit tumour cells and induce vulnerability without disrupting the cytoskeleton is a priority. The antitussive agent noscapine (NOS), known for years, is an emerging prototype for repositioning as a cancer drug. Studies evaluated NOS’s characteristics, mechanisms, effects on chemo-sensitisation, activity patterns, combination strategies, and properties compared to microtubule agents. Unlike taxanes and vinca alkaloids, NOS acts as a soft microtubule stressor, activating the cell’s mitotic checkpoint without collapsing the cytoskeletal network. Based on preclinical models, downstream effects of this mechanism include apoptotic priming, inhibition of angiogenic and survival signalling, modulation of tumour-promoting inflammation, and modulation of resistance. NOS has shown significant effects in hormone-dependent malignancies, multidrug-resistant tumours, hypoxia-related disease settings, and highly proliferative cancers. Nanotechnology-based delivery systems and formulation improvements to improve exposure and tumour targeting may serve these purposes, but they have not been extensively validated in the clinic. The principle behind cytoskeletal machinery drugs is to develop agents capable of inducing stress across multiple mitotic targets. NOS should be considered an investigational antimitotic drug at this point, exhibiting promising mechanistic properties. The results of such an agent require further validation in well-designed Phase II/III studies in an adequate population. The intrinsic translational potency is still limited, as are the pharmacokinetic properties, such as first-pass metabolism and short systemic duration of action; indeed, there is a strong bias towards preclinical evidence.